Decision Resources, Inc., Jan 2010, Pages: 46
position in specialty drugs, emerging markets, and biosimilars/generics. In this report, we assess the health of Midsize Pharma and examine the reasons for the rapid turnover of this group of companies
MP Advisors, Sep 2011, Pages: 80
Tapping biosimilar opportunities
A Follow on biologic (FOB) or Biosimilar, as commonly known, has been one of the most widely discussed topics in the world of pharma in the last few years
Decision Resources, Inc., Feb 2009, Pages: 35
markets and economic instability around the world. As the new year opens, what is the current economic environment? How did the pharma and biotech industries fare on the 2008 stock market compared
Decision Resources, Inc., Feb 2011, Pages: 37
positions at Ciba-Geigy, Merck & Co., Syntex, and Schering-Plough in strategic planning, marketing, and business development.
Expert insight: Peter Wittner provides insights on Big Pharma’s emerging
JZMed Inc., Jan 2009, Pages: 225
industry and market. It investigated in depth the development pattern of service capability and market size of this Chinese industry and first time displayed to the world a complete picture of China pharma
Business Insights, March 2008, Pages: 280
strategicalliances, joint ventures and even mergers between themselves and major pharma companies.
Some key findings from this report...
- Theravance, Inc. is the fastest growing biotechnology company
Bizacumen Inc., Nov 2009, Pages: 292
, and marketing of new pharma and biotech products to combat price fixing and cost escalations. Smaller product life spans, worldwide regulatory challenges, and the increasingly slim deadlines for clinical
Global Industry Analysts, Inc., Jan 2011, Pages: 804
, a six-year historic analysis is provided for these markets.
The report also analyzes the world market for Therapeutic Vaccines for the period 2010 to 2015.
The report profiles 162 companies including
Business Insights, Jan 2010, Pages: 151
products and business alliances which enable them to participate in this evolving field of science
- Identify points of convergence of the pharma, diagnostic and food and drinks markets which may offer new
MP Advisors, Jan 2011, Pages: 391
that have those capabilities.
In the 391 report this research looks at five market sections:
- Rising Stars
- Mature Biotech
- Indian Generics
- Global Pharma
- Japan - Global and Emerging
For each
Biopharm Knowledge Publishing, July 2008, Pages: 140
in each category are picked out to convey how companies are positioning themselves to best exploit these movements.
Chapter 5. Strategic thinking
Global sales by technology shows that biotech sales
CYGNUS Business Consulting & Research, Nov 2010, Pages: 205
of these problems. There are seven key broad areas to leverage the advantages that India offers to the established pharma and biotech industries. These include contract research, R&D alliances, clinical trials, R
Global Industry Analysts, Inc., Oct 2010, Pages: 446
Research Council Plant Biotechnology Institute and
Dow AgroSciences Canada Form StrategicAlliance 87
Syngenta Collaborates with Hubei Biopesticide Engineering
Global Industry Analysts, Inc., Aug 2011, Pages: 279
Therapeutics with Annual Revenues in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) 57
13. REST OF WORLD 58
A.Market Analysis 58
Strategic Corporate Developments 58
B.Market
Global Industry Analysts, Inc., April 2010, Pages: 506
and Tarceva
Combination Therapy II-40
Tiandiren Pharma Begins Construction of Biotech Park II-40
Can-Fite to Commence Phase I/II Trial of CF102 II-40
Celsion’s ThermoDox Obtains Orphan Drug Designation from FDA
Global Markets Direct, Nov 2011, Pages: 102
and information sourced from Global Markets Direct’s proprietary databases, LEO Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from LEO Pharma A/S and industry
